The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance

With sunitinib treatment of metastatic renal cell carcinoma, most patients end up developing resistance over time. Recent clinical trials have shown that individualizing treatment protocols could delay resistance and result in better outcomes. We developed an in vivo xenograft tumor model and compar...

Full description

Bibliographic Details
Main Authors: Harrison Sicheng Lin, Qiang Ding, Zsuzsanna Lichner, Sung Sun Kim, Rola Saleeb, Mina Farag, Ashley Di Meo, Pamela Plant, Mirit Kaldas, Georg Arnold Bjarnason, George Makram Yousef
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Journal of Clinical Medicine
Subjects:
renal cell carcinoma
sunitinib
resistance
treatment scheduling
Online Access:https://www.mdpi.com/2077-0383/11/2/369

Internet

https://www.mdpi.com/2077-0383/11/2/369

Similar Items